Switching Calcitonin Gene–Related Peptide Inhibitors for Migraine Prophylaxis (Last Updated: Mar 31, 2025)
Project Line:
Health Technology Review
Project Status:
Completed
Search
No filters applied.
Cladribine and Natalizumab for Relapsing-Remitting Multiple Sclerosis () (Last Updated: Mar 28, 2025)
Multiple sclerosis (MS) is a chronic autoimmune disease with the following clinical manifestations: demyelination, inflammation, neuronal loss, and gliosis (scarring). Relapsing-remitting multiple...
Project Line:
Reimbursement Review
Project Status:
Active
cladribine (Mavenclad) (Last Updated: Mar 28, 2025)
Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name
Manufacturer
Submission Type
Indications
Brand Name:
Mavenclad
Manufacturer:
EMD Serono, a Division of EMD Inc., Canada
Submission Type:
Initial
Indications:
Multiple Sclerosis, relapsing
bimekizumab (Bimzelx ) (Last Updated: Mar 28, 2025)
Project Line:
Reimbursement Review
Project Status:
Active
Contains:
Brand Name
Manufacturer
Submission Type
Indications
Brand Name:
Bimzelx
Manufacturer:
UCB Canada Inc.
Submission Type:
Initial
Indications:
For the treatment of adult
patients with moderate to severe hidradenitis suppurativa
guselkumab (Tremfya) (Last Updated: Mar 28, 2025)
Project Line:
Reimbursement Review
Project Status:
Active
Contains:
Brand Name
Manufacturer
Submission Type
Indications
Brand Name:
Tremfya
Manufacturer:
Janssen Inc.
Submission Type:
Initial
Indications:
The treatment of adult patients with moderately to severely active ulcerative colitis.
glofitamab (Columvi) (Last Updated: Mar 28, 2025)
Project Line:
Reimbursement Review
Project Status:
Active
Contains:
Brand Name
Manufacturer
Submission Type
Indications
Brand Name:
Columvi
Manufacturer:
Hoffmann-La Roche Limited
Submission Type:
Initial
Indications:
Columvi (glofitamab for injection) in combination with gemcitabine and oxaliplatin for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) who are not candidates for autologous stem cell transplant (ASCT).
talazoparib (Talzenna) (Last Updated: Mar 28, 2025)
Project Line:
Reimbursement Review
Project Status:
Received
Contains:
Brand Name
Manufacturer
Submission Type
Indications
Brand Name:
Talzenna
Manufacturer:
Pfizer Canada ULC
Submission Type:
Initial
Indications:
In combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
lazertinib and amivantamab (Lazcluze and Rybrevant) (Last Updated: Mar 28, 2025)
Project Line:
Reimbursement Review
Project Status:
Active
Contains:
Brand Name
Manufacturer
Submission Type
Indications
Brand Name:
Lazcluze and Rybrevant
Manufacturer:
Janssen Inc.
Submission Type:
Initial
Indications:
LAZCLUZE® (lazertinib) in combination with amivantamab is indicated for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations.
pembrolizumab (Keytruda) (Last Updated: Mar 28, 2025)
Project Line:
Reimbursement Review
Project Status:
Active
Contains:
Brand Name
Manufacturer
Submission Type
Indications
Brand Name:
Keytruda
Manufacturer:
Merck Canada Inc.
Submission Type:
Initial
Indications:
Keytruda is indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma, in combination with carboplatin and paclitaxel and then continued as monotherapy.
durvalumab (Imfinzi) (Last Updated: Mar 28, 2025)
Project Line:
Reimbursement Review
Project Status:
Active
Contains:
Brand Name
Manufacturer
Submission Type
Indications
Brand Name:
Imfinzi
Manufacturer:
AstraZeneca Canada Inc.
Submission Type:
Initial
Indications:
Imfinzi (durvalumab) is currently under review by Health Canada for the following proposed indication: for the treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).